Universität zu Köln

Luecke, Simone, Fottner, Christian, Lahner, Harald, Jann, Henning ORCID: 0000-0003-4095-336X, Zolnowski, Dominik, Quietzsch, Detlef, Grabowski, Patricia, Cremer, Birgit, Maasberg, Sebastian, Pape, Ulrich-Frank ORCID: 0000-0002-5238-8348, Mueller, Hans-Helge, Gress, Thomas Matthias and Rinke, Anja ORCID: 0000-0002-8156-2915 (2022). Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice. Cancers, 14 (11). BASEL: MDPI. ISSN 2072-6694

Full text not available from this repository.

Abstract

Simple Summary Grade 3 neuroendocrine neoplasms (NEN G3) are a rare and heterogeneous subtype of NEN and include poorly differentiated neuroendocrine carcinomas and well-differentiated neuroendocrine tumors G3 (NET G3). Standard chemotherapy with platinum plus etoposide may not be appropriate for all subgroups, but more tailored approaches suffer from the lack of data. In our study, we provide real-world data from a large center-based cohort of the German NET Registry and hope to stimulate efforts to conduct clinical trials for well-defined entities. Background: Neuroendocrine neoplasia grade 3 (NEN G3) represents a rare and heterogeneous cancer type with a poor prognosis. The aim of our study was to analyze real-world data from the German NET Registry with a focus on therapeutic and prognostic aspects. Methods: NEN G3 patients were identified within the German NET Registry. Demographic data and data on treatments and outcomes were retrieved. Univariate analyses were performed using the Kaplan-Meier-method. Multivariate analysis was performed using a Cox proportional hazard model. Results: Of 445 included patients, 318 (71.5%) were diagnosed at stage IV. Well-differentiated morphology (NET G3) was described in 31.7%, 60% of cases were classified as neuroendocrine carcinoma (NEC), and the median Ki67 value was 50%. First-line treatment comprised chemotherapy in 43.8%, with differences in the choice of regimen with regard to NET or NEC, and surgery in 41.6% of patients. Median overall survival for the entire cohort was 31 months. Stage, performance status and Ki67 were significant prognostic factors in multivariate analysis. Conclusions: The survival data of our national registry compare favorably to population-based data, probably mainly because of a relatively low median Ki67 of 50%. Nevertheless, the best first- and second-line approaches for specific subgroups remain unclear, and an international effort to fill these gaps is needed.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Luecke, Simone UNSPECIFIED UNSPECIFIED UNSPECIFIED Fottner, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Lahner, Harald UNSPECIFIED UNSPECIFIED UNSPECIFIED Jann, Henning UNSPECIFIED orcid.org/0000-0003-4095-336X UNSPECIFIED Zolnowski, Dominik UNSPECIFIED UNSPECIFIED UNSPECIFIED Quietzsch, Detlef UNSPECIFIED UNSPECIFIED UNSPECIFIED Grabowski, Patricia UNSPECIFIED UNSPECIFIED UNSPECIFIED Cremer, Birgit UNSPECIFIED UNSPECIFIED UNSPECIFIED Maasberg, Sebastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Pape, Ulrich-Frank UNSPECIFIED orcid.org/0000-0002-5238-8348 UNSPECIFIED Mueller, Hans-Helge UNSPECIFIED UNSPECIFIED UNSPECIFIED Gress, Thomas Matthias UNSPECIFIED UNSPECIFIED UNSPECIFIED Rinke, Anja UNSPECIFIED orcid.org/0000-0002-8156-2915 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-691322
DOI:	10.3390/cancers14112718
Journal or Publication Title:	Cancers
Volume:	14
Number:	11
Date:	2022
Publisher:	MDPI
Place of Publication:	BASEL
ISSN:	2072-6694
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language RECEPTOR RADIONUCLIDE THERAPY; CELL LUNG-CANCER; PROGNOSTIC-FACTORS; 2ND-LINE CHEMOTHERAPY; CONSENSUS GUIDELINES; G3; CARCINOMAS; TUMORS; ETOPOSIDE; COMBINATION Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69132